(NASDAQ: IONS) Ionis Pharmaceuticals's forecast annual revenue growth rate of 28.25% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.33%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.34%.
Ionis Pharmaceuticals's revenue in 2026 is $1,058,189,000.On average, 27 Wall Street analysts forecast IONS's revenue for 2026 to be $150,957,429,153, with the lowest IONS revenue forecast at $142,426,576,012, and the highest IONS revenue forecast at $164,328,822,559. On average, 25 Wall Street analysts forecast IONS's revenue for 2027 to be $255,826,436,688, with the lowest IONS revenue forecast at $198,976,117,424, and the highest IONS revenue forecast at $356,801,858,404.
In 2028, IONS is forecast to generate $371,014,438,220 in revenue, with the lowest revenue forecast at $286,895,797,216 and the highest revenue forecast at $534,954,893,772.